ABSTRACT
To observe and analyze therapeutic effect of valsartan combined beraprost sodium on patients with hypertension (EH) complicated early renal injury (ERI).Methods : A total of 480 EH + ERI patients treated in our hospital in near two years were randomly and equally divided into valsartan group and combined treatment group (received valsartan combined beraprost sodium) , both groups were treated for three months .Levels of blood pressure , renal function related indexes were compared between two groups before and after treatment .Results :Compared with before treatment , after three months , there were significant reductions in levels of blood pressure , serum creatinine , urine β2 microglobulin and D‐dimer , and significant rise in creatinine clearance rate (Ccr) in two groups , P＝0.001 all.Compared with valsartan group after treatment , there were significant reductions in levels of blood pressure [ (130. 92 ± 5.92)／(80.18 ± 6.69) mmHg vs.(120. 93 ± 6. 53)／(69.98 ± 6.32) mmHg] , serum creatinine [ (93.92 ± 10. 49) μmol／L vs.(83. 14 ± 11. 03) μmol／L] , urine β2 microglobulin [ (385.41 ± 35.54) μg／L vs.(362.65 ± 26.59) μg／L] and D‐dimer [ (1. 75 ± 0.44) mg／L vs.(1. 01 ± 0.11) mg／L] , and significant rise in Ccr [ (63.22 ± 7. 66) ml／min vs.(79.13 ± 8.83) ml／min] in combined treatment group , P＝0.001 all.Conclusion :Compared with valsartan monotherapy , valsartan combined beraprost sodium can more significantly reduce blood pressure and protect renal function in hypertensive patients with early renal injury .
ABSTRACT
BACKGROUND: To evaluate the changes in cardiovascular risk markers including pulse wave velocity (PWV), microalbuminuria, inflammatory cytokines, and adhesion molecules after treatment with beraprost sodium (BPS) in patients with diabetic nephropathy.METHODS: This was a multicenter, prospective, randomized, double-blind, placebo-controlled trial. Type 2 diabetes mellitus patients with microalbuminuria were included. The primary endpoints were changes in microalbuminuria in spot urine and PWV after BPS or placebo (PCB) treatment for 24 weeks. The secondary endpoints were changes in clinical and metabolic parameters.RESULTS: A total of 52 patients completed the 24-week trial. Changes in PWV were not different significantly in the BPS and PCB groups (right, P=0.16; left, P=0.11). Changes in microalbuminuria were 14.2±157.0 and 34.5±146.6 (µg/mg Cr) in the BPS and PCB groups, respectively (P=0.63). Subgroup analysis in the high blood pressure (BP) group (baseline systolic BP >120 mm Hg and diastolic BP >80 mm Hg), showed that microalbuminuria decreased by −47.6 in the BPS group compared with an increase by 116.4 (µg/mg Cr) in the PCB group (P=0.04). Also, in the large waist circumference group (>95 cm), microalbuminuria decreased significantly in the BPS group (P=0.04).CONCLUSION: Short-term treatment of BPS for patients with diabetic nephropathy did not show significant improvement in various cardiovascular risk factors. However, BPS significantly decreased microalbuminuria in study subjects with higher cardiovascular risk such as high BP or large waist circumference.
Subject(s)
Humans , Cytokines , Diabetes Mellitus, Type 2 , Diabetic Nephropathies , Hypertension , Prospective Studies , Pulse Wave Analysis , Risk Factors , Sodium , Vascular Stiffness , Waist CircumferenceABSTRACT
PURPOSE: This study examined the effects of beraprost sodium on digital infrared thermal images in patients with peripheral arterial disease caused by type 2 diabetes mellitus. MATERIALS AND METHODS: Twenty-five diabetic patients with peripheral arterial disease were treated with beraprost sodium in a prospective, multicenter, cohort study from February 2013 to December 2014. Beraprost sodium (40 μg) was administered orally 3 times daily (120 μg/day) for 6 months. The visual analogue scale (VAS) and digital infrared thermal imaging (DITI) were performed to compare the blood flow improvement between before and after dosing. RESULTS: Among the 25 patients included in the evaluation, 22 patients completed the study. A significant increase in body temperature was observed in the front and left side, particularly in the plantar side in DITI compared to that before and after administration. An increase in body temperature was observed at the frontal part from 28.1℃±2.3℃ to 29.1℃±2.1℃ (p=0.021), at the left side from 27.8℃±2.4℃ to 28.6℃±1.9℃ (p=0.028), at the plantar part at 24.0℃±1.5℃, and at the plantar part at 27.1℃±2.4℃ (p < 0.01). The VAS decreased significantly from 5.4±1.3 to 2.7±2.0 after 6 months of treatment (p < 0.01). CONCLUSION: Beraprost sodium is a safe and easy-to use oral medication for diabetes peripheral arterial disease. It can be expected to increase the blood flow and decrease the lower extremity pain statistically after being taken for 6 months.
Subject(s)
Humans , Body Temperature , Cohort Studies , Diabetes Mellitus, Type 2 , Lower Extremity , Peripheral Arterial Disease , Prospective Studies , SodiumABSTRACT
Objective; To explore the clinical efficacy and safety of beraprost sodium (BPS) combined with glucocorticoid (GC) and (or) immunosuppressive agents in the treatment of the patients with primary nephrotic syndrome (PNS), and to provide evidence for its application in the treatment of PNS. Methods; Eighty-six patients diagnosed as PNS definitely were selected. They were treated with GC and (or) immunosuppressive agents and were divided into BPS group (administrated with BPS, ra=42) and control group (administrated with dipyridamole or aspirin, n-) according to their willing to the acceptance of different anti-platelet treatment regimens. The relevant laboratory indexes of the patients in two groups before and after treatment were analyzed, and the effective rate, incidence of complications and drug adverse reactions of the patients in two groups were compared. Results; Comparedwith control group, the urinary protein levels of the patients in BPS group at the 1st and 6th months after treatment were significantly decresed (P<0. 05) and the serum albumin (ALB) levels of the patients in BPS group were significantly increased (P<0. 05); the levels of fibrinogen (FIB) and D-dimer (DD) of the patients in BPS group at the 3rd, 6th and 12th months after treatment were significantly decreased (P<0. 05 or P<0. 01). Compared with control group, the systolic blood pressure (SBP) and diastolic blood pressure (DBP) of the patients in BPS group at the 1st month after treatment were decreased significantly (P<0. 05). The cholesterol (TC) level and total effective rate of the patients in BPS group at the 6th month after treatment were higher than those in control group (P<0. 05). Compared with control group, the incidence of elevation of blood pressure of the patients with normal basal blood pressure in BPS group was significantly decreased (P<0. 05); the incidence of headache and dizziness was significantly increased (P<0. 05). Conclusion: The safety of BPS combined with GC and (or) immunosuppressive agents in treating the PNS patients is higher and superior to the conventional antiplatelet agents.
ABSTRACT
OBJECTIVE:To observe clinical efficacy and safety of Compound xiongshao capsules in the treatment of diabetic peripheral neuropathy (DPN).METHODS:A total of 97 DPN patients selected from our hospital during Jun.2015-Apr.2016 were divided into group A (compound xiongshao treatment group,46 cases) and control group (51 cases) according to random number table.The latter was divided into group B (epalrestat+beraprost sodium group,12 cases),group C (fursultiamine+mecobalamin group,12 cases) and group D (epalrestat group,27 cases) according to clinical symptoms and economic situation of patients.Four groups were given antidiabetic drugs for blood glucose control.Based on it,group A was additionally given Compound xiongshao capsules 0.9 g,tid;group B was additionally given Epalrestat tablets 50 mg,tid+Beraprost sodium tablets 40 μg,tid;group C was additionally given Fursultiamine tablets 50 mg,tid+Mecobalamin tablets 0.5 mg,rid;group D was additionally given Epalrestat tablets 50 mg,tid.All groups were treated for 6 months.Clinical efficacies were observed.TCSS scores,motor nerve conduction velocity (MCV),sensory nerve conduction velocity (SCV),incubation period and amplitude of median nerve and common peroneal nerve,the levels of hemorheology indexes,blood glucose,glycosylated hemoglobin,blood lipid,serum creatinine were compared before and after treatment.The occurrence of ADR was recorded.RESULTS:Total response rates of group A and B (82.61％,83.33％)were significantly higher than those of group C and D (33.33％,66.67％),total response rate of group D was significantly higher than that of group C,with statistical significance (P＜0.05).Before treatment,there was no statistical significance in TCSS scores,MCV,SCV,incubation period and amplitude of median nerve,MCV and amplitude of common peroneal never,SCV,incubation period and amplitude of common peroneal never or whole blood high-shear viscosity among 4 groups (P＞0.05).After treatment,TCSS scores of group A,B and D were decreased significantly compared to before treatment,and those of group A and B were lower than those of group C and D,with statistical significance (P＜0.05).MCV,incubation period and amplitude of median nerve in group A and B,amplitude of median nerve in group C,MCV and amplitude of median nerve in group D were significantly better than before treatment;MCV,incubation period and amplitude of median nerve in group A and B were significantly better than group C and D,with statistical significance (P＜0.05).MCV,incubation period and amplitude of common peroneal never in group A,B,C were significantly better than before treatment,MCV and amplitude of common peroneal never in group A,B were significantly better than group C,D;the improvement of incubation period of common peroneal never in group A,B,D were significantly better than group C,with statistical significance (P＜0.05).SCV,incubation period and amplitude of median nerve,SCV and amplitude of common peroneal nerve in group A,B and D were significantly better than before treatment;SCV,incubation period and amplitude of median nerve,SCV and amplitude of common peroneal nerve in group A,SCV,incubation period and amplitude of median nerve and amplitude of common peroneal nerve in group B were significantly better than group C and D;SCV of median nerve in group D was significantly better than group C,with statistical significance (P＜0.05).Whole blood high-shear viscosity of group A was decreased significantly compared to before treatment,and significantly lower than those of group B,C and D,with statistical significance (P＜0.05).There was no statistical significance in total response rate and TCSS score between group A and B,and in the levels of blood glucose,glycosylated hemoglobin,blood lipid or serum creatinine among 4 groups (P＞0.05).No obvious ADR was found in 4 groups.CONCLUSIONS:Compound xiongshao capsules shows significant therapeutic efficacy for DPN,and improves nerve conduction velocity,incubation period and amplitude of median nerve and common peroneal nerve,whole blood high-shear viscosity.Its effect is similar to that of epalrestat combined with beraprost sodium,and better than those of fursultiamine combined with mecobalamin,epalrestat alone.It does not affect the blood glucose,blood lipid and serum creatinine levels with good safety.
ABSTRACT
Objective To evaluate the effectiveness of Beraprost sodium and its impact on vascular endothelial dysfunction in elderly patients with diabetic peripheral neuropathy (DPN).Methods A total of 86 elderly patients (age≥60 years) with DPN were recruited and randomly assigned into a control group (n=43) and a treatment group (n=43).Both groups received regular treatments including drug treatment such as glucose-lowering,lip-lowering,anti-platelet and neurotropic medications,and non-drug treatment measures such as smoking cessation and foot massage.In addition,the treatment group was given 40 μg oral Beraprost sodium three times a day for 90 days.Data on vibrating perception threshold (VPT),transcutaneous oxygen (tcpO2),ankle-brachial index (ABI),liver and kidney function,hemoglobin A1c (HbA1c),serum nitric oxide (NO) and endothelin-1 (ET-1) were collected before and after treatment.Results No adverse reaction was observed during the experiment.After 90-day treatment,both the control group and the treatment group showed decreased VPT values (F =23.06,195.13,both P ＜0.01),increased tcpO2 values (F =304.65,594.33,both P＜0.01),increased ABI (F=119.24,336.60,both P＜0.01),increased serum NOlevels (F =375.48,741.20,both P＜0.01),and decreased serum ET-1 levels (F=49.07,211.24,both P＜0.01).Compared with the control group,the value of VPT (F=25.16,P＜0.01)and the level of ET-1(F=61.83,P＜0.01) were significantly lower,while the level of NO and the values of tcpO2 and ABI were significantly higher (F =24.06,62.82,21.46,all P ＜ 0.01) in the treatment group.Conclusions Oral beraprost sodium can be effectively and safely used in DNP patients,and it can also alleviate endothelial dysfunction.
ABSTRACT
Patients with an atrial septal defect (ASD) and severe pulmonary arterial hypertension (PAH) are considered ineligible for defect closure surgery because of the risk of right ventricular decompensation and death after the operation. We report the case of a patient with large ASD and severe PAH who was able to undergo defect closure surgery successfully following long-term use of combined oral sildenafil and beraprost.
Subject(s)
Humans , Heart Defects, Congenital , Heart Septal Defects, Atrial , Hypertension , Hypertension, Pulmonary , Sildenafil CitrateABSTRACT
Patients with an atrial septal defect (ASD) and severe pulmonary arterial hypertension (PAH) are considered ineligible for defect closure surgery because of the risk of right ventricular decompensation and death after the operation. We report the case of a patient with large ASD and severe PAH who was able to undergo defect closure surgery successfully following long-term use of combined oral sildenafil and beraprost.
Subject(s)
Humans , Heart Defects, Congenital , Heart Septal Defects, Atrial , Hypertension , Hypertension, Pulmonary , Sildenafil CitrateABSTRACT
OBJECTIVE:To observe the clinical efficacy and safety of beraprost combined with fibrinogenase in the treatment of lower extremity atherosclerotic occlusive disease(LEAOD).METHODS:A total of 82 LEAOD patients selected from our hospital dur-ing Jan. 2015-Jan. 2016 were divided into control group and observation group according to random number table,with 41 cases in each group.All patients received low salt and low fat diet on the basis of treatment for primary disease.Control group was additionally given Fibrinogenase injection 200 U,ivgtt,qd;observation group was additionally given Beraprost sodium tablets 40 μg,tid,after meal,on the basis of control group.Both groups were treated for 15 d.Clinical efficacies as well as hemorheological indexes,ankle-brachial indexes,pain scores,cold felling scores,intermittent claudication scores and serum oxidation stress indexes before and after treatment were compared between 2 groups. The occurrence of ADR was also recorded. RESULTS:Total response rate of observation group (90.24%)was significantly higher than that of control group(78.05%),with statistical significance(P<0.05). Before treatment, there was no statistical significance in above indexes between 2 groups(P>0.05).Compared to before treatment,whole blood high shear viscosity,plasma viscosity,hematocrit,fibrinogen contents,platelet adhesion rates,pain scores,cold feeling scores,intermit-tent claudication scores and serum MDA levels of 2 groups were decreased significantly after treatment;while ankle-brachial indexes, the serum levels of SOD,T-AOC and GSH-Px were increased;the indexes of observation group were better than those of control group,with statistical significance(P<0.05).There was no statistical significance in the incidence of ADR between 2 groups(P>0.05).CONCLUSIONS:Beraprost combined with fibrinogenase show good therapeutic efficacy for LEAOD,can effectively relieve clinical symptoms,promote local blood circulation and improve oxidant stress level with good safety.
ABSTRACT
OBJECTIVE:To observe the clinical efficacy and safety of beraprost combined with fibrinogenase in the treatment of lower extremity atherosclerotic occlusive disease(LEAOD).METHODS:A total of 82 LEAOD patients selected from our hospital dur-ing Jan. 2015-Jan. 2016 were divided into control group and observation group according to random number table,with 41 cases in each group.All patients received low salt and low fat diet on the basis of treatment for primary disease.Control group was additionally given Fibrinogenase injection 200 U,ivgtt,qd;observation group was additionally given Beraprost sodium tablets 40 μg,tid,after meal,on the basis of control group.Both groups were treated for 15 d.Clinical efficacies as well as hemorheological indexes,ankle-brachial indexes,pain scores,cold felling scores,intermittent claudication scores and serum oxidation stress indexes before and after treatment were compared between 2 groups. The occurrence of ADR was also recorded. RESULTS:Total response rate of observation group (90.24%)was significantly higher than that of control group(78.05%),with statistical significance(P<0.05). Before treatment, there was no statistical significance in above indexes between 2 groups(P>0.05).Compared to before treatment,whole blood high shear viscosity,plasma viscosity,hematocrit,fibrinogen contents,platelet adhesion rates,pain scores,cold feeling scores,intermit-tent claudication scores and serum MDA levels of 2 groups were decreased significantly after treatment;while ankle-brachial indexes, the serum levels of SOD,T-AOC and GSH-Px were increased;the indexes of observation group were better than those of control group,with statistical significance(P<0.05).There was no statistical significance in the incidence of ADR between 2 groups(P>0.05).CONCLUSIONS:Beraprost combined with fibrinogenase show good therapeutic efficacy for LEAOD,can effectively relieve clinical symptoms,promote local blood circulation and improve oxidant stress level with good safety.
ABSTRACT
Objective To explore the effect of beraprost sodium (BPS) on hypoxia-induced pulmonary artery hypertension (HPH) in rats and the expression of oxygen-sensitive Kv channels in pulmonary artery smooth muscle (PASM).Methods The HPH model of rats was established by exposing rats to low-pressure and low-oxygen cabin which was auto-modulated for 8h every day.Rats in the BPS group were given an intragastric administration of BPS [300 μg/(kg · d)],while those in the control group and HPH group were given an intragastric administration of 3 ml/kg of 0.9％ saline.After 4 weeks,the mean pulmonary artery pressure (mPAP) was measured and right heart ventricle hypertrophy index (RVHI) was calculated;pulmonary artery remodeling was evaluated by HE staining;the expressions of Kv 1.2,Kv 1.5 and Kv2.1 in the pulmonary artery were detected by Real-time PCR and Western blot.Results The HPH model was successfully established in rats exposed to chronic hypoxia for 4 weeks.Compared with those in HPH group,mPAP,RVHI and pulmonary artery remodeling were decreased in BPS group [mPAP:(13.48±2.18)mmHg vs.(23.87±2.23)mmHg vs.(17.09±1.20)mmHg;RVHI:0.28±0.02 vs.0.46±0.03 vs.0.36±0.04;％ area of medial smooth muscle:35.72±6.58 vs.68.52±5.64 vs.46.58±8.43;P＜0.05],and the mRNA and protein expressions of Kv 1.2,Kv 1.5 and Kv 2.1 were increased (relative protein expression level:Kv1.2,0.78±0.10 vs.0.15±0.03 vs.0.57±0.13;Kv1.5,0.61±0.10 vs.0.31±0.05 vs.0.59±0.13;Kv2.1,0.29±0.05 vs.0.10±0.02 vs.0.28±0.07;P＜0.05).Conclusion BPS can improve pulmonary arterial hypertension induced by hypoxia,and upregulate the decreased mRNA and protein expressions of Kv 1.2,Kv 1.5 and Kv 2.1 in pulmonary artery.
ABSTRACT
Objective To study the effect of blood coagulation function and nerve function of beraprost in the treatment of acute cerebral infarction.Methods 80 cases of acute cerebral infarction were randomly divided into 2 groups, 40 cases in the control group and 40 cases in the experiment group.The control group received routine treatment, the experiment group were treated with the same as the control group combined with beraprost.Changes of coagulation function and nerve function were compared pre-and post-treatment between two groups.Results Compared with pre-treatment, APTT, PT, Fib level, serum NGF level, Barthel score increased post-treatment of the two groups, D-D, serum NSE, S100b, NIHSS score decreased, compared with the control group, APTT, PT, Fib level, serum NGF level, Barthel score were higher in the experiment group, the total effective rate was higher than the control group, two D-D, serum NSE, S100β, NIHSS scores were lower than the control group, the differences were statistically significant (P<0.05).Conclusion Beraprost can reduce the high coagulation state in patients with acute cerebral infarction, improve the degree of neurological impairment, and has good clinical efficacy.
ABSTRACT
Objective To explore the effects of beraprost sodium (BPS) on angiotensin Ⅱ(AngⅡ)-induced podocyte apoptosis and the relationship between BPS and peroxisome proliferator activated receptor δ(PPARδ). Methods Differentiated mouse podocytes were exposed to AngⅡ, further treated with BPS (or GSK0660) for 24 h. Podocyte apoptosis was detected by flow cytometry and AnnexinV-FITC staining. Bax , Bcl-2 and PPARδ mRNA were assessed by RT-PCR. Results AngⅡ promoted podocyte apoptosis and Bax mRNA expression significantly, down-regulated Bcl-2 and inhibited PPARδ mRNA (P < 0.05). Conversely, treatment with BPS reduced AngⅡ-induced podocyte apoptosis and Bax mRNA expression and promoted Bcl-s expression significantly resulting in an increase of PPARδ mRNA expression (P < 0.05). With the inhibition of PPARδ, podocyte apoptosis and Bax mRNA expression increased while Bcl-2 mRNA expression reduced. Conclusion BPS can effectively reduce AngⅡ-induced podocyte apoptosis , which is associated with the activation of PPARδand regulation of Bcl-2/Bax mRNA expression.
ABSTRACT
Objective To study and analyze the efficacy and adverse reactions of beraprost sodium combined with aspirin in the treatment of diabetic foot.Methods 90 cases with diabetic foot were selected and they were randomly divided into the observation group and control group,35 cases in each group.Two groups were both treated with basic treatment.On the basis of the basic treatment,the control group was given aspirin,while the observation group was treated with beraprost sodium combined with aspirin.The clinical efficacy,ulcer healing rate,ankle back index,transcutaneous oxygen pressure,average healing time and the occurrence of adverse reactions were compared between the two groups.Results The clinical effective rate of the observation group was 93.3％ (42/45),which was significantly higher than 84.4％ (38/45) of the control group,the difference between the two groups was statistically significant (x2 =8.030,P ＜ 0.05).The wound healing rate,ankle dorsal index,average healing time,the degree of improvement of transcutaneous and oxygen pressuer of the observation group were (81.4 ± 2.7) ％,(11.2 ± 2.1),(39.1 ± 2.1) d and (26.3 ± 1.8) mmHg,which were significantly better than (69.3 ± 1.9) ％,(8.4 ± 2.9) ％,(52.3 ± 8.2) d and (16.3 ± 2.6)mmHg of the control group.The differences of these indicators between the two groups were statistically significant(t =12.72,7.92,12.06,9.97,P ＜ 0.05).The difference of adverse reactions between the two groups was not statistically significant (P ＞ 0.05).Conclusion Beraprost sodium combined with aspirin has better clinical efficacy in the treatment of diabetic foot.It can improve the patients'ulcer healing rate,the ankle back index,transcutaneous oxygen pressure,shorter the average healing time,and it has few adverse reactions.
ABSTRACT
Objective To explore the effect of the combination of benazepril and beraprost sodium on urinary microalbumin (UMA), serum high sensitivity C-reactive protein (hs-CRP) and TNF-α in patients with diabetic nephropathy(DN) in early stage. Methods From Mar. 2010 to Mar. 2013, 120 patients with early-stage DN were randomly divided into Benazepril Group, Beraprost Sodium Group and Combination Group. Each group consisted of 40 patients with medical therapy in 20-week duration. The levels of 24 h-UMA, serum hs-CRP and TNF-α were detected and compared before and after therapy. Results After treatment, the levels of 24 h-UMA, serum hs-CRP and TNF-αall decreased significantly in three groups (P<0.05) and there were lower 24 h-UMA, serum hs-CRP and TNF-αin Combination Group than those in Benazepril Group and Berapros sodium Group (P <0.05). Conclusion There is coordinating protection of combination of benazepril and beraprost sodium on diabetic nephropathy in early stage, possibly being related with the inhibiting of micro-inflammation.
ABSTRACT
Aim To investigate the protective effects of beraprost sodium on cerebral cortical neuron injury in chronic aluminum-overload rats and its effects on PGIS-IP signaling pathway. Methods 75 SD rats were randomized into five groups: normal control group, chronic aluminum-overload group ( model group) and beraprost sodium groups-low dose (6 μg· kg-1 ), medium dose ( 12 μg · kg-1 ) and high dose (24 μg·kg-1). Aluminum gluconate (Al3+ 200 mg ·kg-1 d-1, once a day, 5d a week, for 20 weeks, p. o. ) was administered to rats of cerebral damage model. The rats of experimental groups were concomi-tantly treated with beraprost sodium ( p. o. ) daily for 20 weeks. After the model was built successfully, the spatial learning and memory( SLM) function was done by Morris water maze. The cortical neurons damage was detected by HE staining, SOD activities and MDA contents. The 6-k-PGF1α levels in cortex were meas-ured by ELISA. The expressions of PGIS, IP mRNA and IP protein were also studied. Results Compared with the rats of normal control group, the SLM function was significantly impaired ( P<0. 01 ) and considera-ble karyopycnosis was observed in model group rats. The SOD activities were weakened ( P <0. 01 ), the MDA contents increased ( P<0. 05 ) and the levels of 6-k-PGF1α raised significantly ( P <0. 01). The ex-pressions of PGIS and IP mRNA in the rats cortex obvi-ously increased ( P<0. 01 ), so did the expression of IP protein(P<0. 05). Compared with the rats of mod-el group, the SLM function of rats in experimental groups decreased significantly ( P<0. 01 ) and damage of cortical neurons reduced remarkably. The SOD ac-tivities increased ( P <0. 01 ) and the MDA contents decreased ( P <0. 01). Besides, the content of 6-k-PGF1α, the expressions of PGIS mRNA and IP protein in the rats cortex decreased significantly ( P<0. 05 ) as well as IP mRNA ( P<0. 01). Conclusion Our re-sults demonstrate that in cerebral cortical neuron of chronic aluminum-overload rats, beraprost sodium has notably protective effects and the mechanism might be related to PGIS-IP signaling pathway.
ABSTRACT
Objective To investigate the effect of Beraprost Sodium and atorvastatin in the treatment of TIA combined carotid plaques. Method 60 cases in our hospital with TIA and carotid artery plaques were randomly divided into observation group and control group, 30 cases in each group. The observation group was received beraprost natriuretic peptide and atorvastatin calcium therapy, the control group was treated with atorvastatin calcium. 12 months later,two groups were compared with carotid plaque area change and coagulation conditions. Results Carotid plaque area in observed group was significantly less than the control group (P<0.05). The differences of platelet agglutination test(PAgT), fibrinogen(Fg) , hypersensieive 3 C-reaction protein, total cholesterol(TC), high density lipoprotein cholesterol (HDL), low density lipoprotein cholesterol (LDL), TIA recurrence rate and incidence of ischemic stroke between two groups after treatment were statistically significant (P<0.05). Conclusion Beraprost Sodium and atorvastatin has a good effect in reducing carotid plaques area, adjusting blood fat and preventing TIA and ischemic stroke, It is worthy to clinical popularization and application.
ABSTRACT
BACKGROUND: This study evaluated the effects of Beraprost sodium (Berasil) on subjective leg symptoms in patients with peripheral arterial disease caused by diabetes mellitus. METHODS: Ninety-four diabetic patients with peripheral arterial disease were treated with Beraprost in a fixed-dose, prospective, multicenter, cohort study. Beraprost (40 microg) was administered orally 3 times daily (120 microg/day) for 12 weeks. We developed a new disease-specific symptom questionnaire, which evaluated the effect of peripheral arterial disease on leg discomfort in daily life and assessed therapeutic responses to treatment. Patients were asked for their subjective assessment of symptoms on a written questionnaire before treatment and after 12 weeks of therapy. RESULTS: There was significant improvement in all estimated subjective symptoms (burning, coldness, edema, exertional pain, stabbing, and paresthesias) in the lower extremities at 12 weeks (p < 0.001). There were 18 patients with neuropathy in whom significant improvement was noted for 6 subjective symptoms at 12 weeks (p < 0.05). Adverse events considered to be drug-related were observed in 4 patients (4.3%), all of which were mild and resolved with discontinuation of the medication. CONCLUSIONS: Beraprost is effective as a treatment for improving various subjective symptoms in the lower extremities, such as burning, coldness, edema, exertional pain, stabbing, and paresthesias, in diabetic patients with peripheral arterial disease.
Subject(s)
Adult , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Cohort Studies , Diabetes Complications/drug therapy , Epoprostenol/analogs & derivatives , Peripheral Arterial Disease/complications , Platelet Aggregation Inhibitors/therapeutic use , Prospective Studies , Statistics, NonparametricABSTRACT
Objective To observe the effect of beraprost sodium on elderly patients with type 2 diabetic nephropathy (DN) and to observe the change of the plasma vascular endothelial growth factor(VEGF) and endothelin(ET-1) level.Methods The levels of plasma VEGF and ET-1 in the 27 cases of type 2 diabetes without nephropathy and 48 cases with type 2 diabetic nephropathy were measured.The possible role of VEGF and ET-1 in diabetic nephropathy was explored.48 cases of type 2 diabetic nephropathy patients were randomly divided into 2 groups:the conventional treatment group and beraprost sodium treatment group.The changes of VEGF and ET-1 level in the 2 groups before and after the treatment were measured.Results The plasma VEGF and ET-1 levels were significantly higher in type 2 diabetic nephropathy patients than in type 2 diabetes patients without nephropathy(P ＜0.01).Compared with the control group,beraprost sodium significantly reduced the plasma VEGF and ET-1 levels in patients with diabetic nephropathy(P ＜ 0.05),and also reduced urinary albumin excretion rates (UAER) significantly (P ＜ 0.05).Conclusions The increasing level of VEGF and ET-1 plays an important role in the onset of diabetic nephropathy.Beraprost sodium can correct the balance of the plasma VEGF and ET-1 in treatment of patients with diabetic nephropathy,improves the endothelial function in diabetic nephropathy,decreases urine protein,and plays a protective role in diabetic nephropathy.
ABSTRACT
BACKGROUND: Pulmonary vascular changes which occur early in the course of chronic obstructive pulmonary disease (COPD) are prevalent manifestation and later cause pulmonary hypertension, which is a bad prognostic factor in COPD. Beraprost sodium (BPS), an orally active prostacyclin analogue, has been shown to improve survival in patients with primary pulmonary hypertension. This study investigated the effect of BPS in the patients with COPD. METHODS: This is a double-blind randomized placebo-controlled, two center clinical trial. Twenty one consecutive patients with COPD were enrolled from June 2003 to June 2004 (patients treated with BPS for 3 months, BPS group, n=11; those with placebo, placebo group, n=10). The baseline demographic, pulmonary function and hemodynamic data were not significantly different between two groups. RESULTS: On echocardiographic examination, trans tricuspid valve pressure gradient has decreased significantly after 3 months with beraprost in the BPS group [17.7(+/-11.4) to 8.2(+/-8.9) mm Hg, p-value<0.05], while there was no significant change in the control group. Six-minute walking distance has decreased in the control group and increased in the BPS group, but there was no statistical significance. CONCLUSION: In patients with COPD oral administration of BPS reduced the pulmonary arterial pressure. The clinical significance of this finding, that is improving symptoms and natural course of the disease, needs further study.